Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

ABSTRACT:

Background

Prior studies with the use of a prospective-retrospective design including archival tumor samples have shown that gene-expression assays provide clinically useful prognostic information. However, a prospectively conducted study in a uniformly treated population provides the highest level of evidence supporting the clinical validity and usefulness of a biomarker.

Methods

We performed a prospective trial involving women with hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary node-negative breast cancer with tumors of 1.1 to 5.0 cm in the greatest dimension (or 0.6 to 1.0 cm in the greatest dimension and intermediate or high tumor grade) who met established guidelines for the consideration of adjuvant chemotherapy on th

SUBMITTER: Sparano JA 

PROVIDER: S-EPMC4701034 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature